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Abstract
Objective: The effects of obesity in liver transplantation remain controversial. Earlier institutional data
demonstrated no significant difference in postoperative complications or 1-year mortality. This study was
conducted to test the hypothesis that obesity alone has minimal effect on longterm graft and overall
survival.
Methods: A retrospective, single-institution analysis of outcomes in patients submitted to primary adult
orthotopic liver transplantation was conducted using data for the period from 1 January 2002 to 31
December 2012. Recipients were divided into six groups by pre-transplant body mass index (BMI),
comprising those with BMIs of <18.0 kg/m2, 18.0–24.9 kg/m2, 25.0–29.9 kg/m2, 30.0–35.0 kg/m2, 35.1–
40.0 kg/m2 and >40 kg/m2, respectively. Pre- and post-transplant parameters were compared. A P-value
of <0.05 was considered to indicate statistical significance. Independent predictors of patient and graft
survival were determined using multivariate analysis.
Results: A total of 785 patients met the study inclusion criteria. A BMI of >35 kg/m2 was associated with
non-alcoholic steatohepatitis (NASH) cirrhosis (P < 0.0001), higher Model for End-stage Liver Disease
(MELD) score, and longer wait times for transplant (P = 0.002). There were no differences in operative time,
intensive care unit or hospital length of stay, or perioperative complications. Graft and patient survival at
intervals up to 3 years were similar between groups. Compared with non-obese recipients, recipients with
a BMI of >40 kg/m2 showed significantly reduced 5-year graft (49.0% versus 75.8%; P < 0.02) and patient
(51.3% versus 78.8%; P < 0.01) survival.
Conclusions: Obesity increasingly impacts outcomes in liver transplantation. Although the present data
are limited by the fact that they were sourced from a single institution, they suggest that morbid obesity
adversely affects longterm outcomes despite providing similar short-term results. Further analysis is
indicated to identify risk factors for poor outcomes in morbidly obese patients.
Received 28 April 2014; accepted 18 August 2014
Correspondence
William C. Chapman, Section of Abdominal Transplantation, Department of Surgery, Washington
University, 660 South Euclid Avenue, Box 8109, St Louis, MO 63110, USA. Tel: + 1 314 362 2538. Fax: +
1 314 361 4197. E-mail: chapmanw@wustl.edu
Introduction
The national obesity epidemic continues to progress at an alarm-
ing rate, affecting 78 million adult Americans. The prevalence of
obesity amongst potential liver transplant recipients is also rising;
more than half are overweight or obese.1 The full impact of this
chronic health condition in the context of liver transplantation is
yet to be determined. Non-alcoholic steatohepatitis (NASH), the
hepatic manifestation of obesity and metabolic syndrome, is now
the fourth leading indication for orthotopic liver transplantation
(OLT) in the USA and accounted for 7.4% of OLTs performed in
2010.2 Non-alcoholic steatohepatitis is predicted to surpass hepa-
titis C as the leading indication for OLT in the next 10 years.3,4 An
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estimated 25 million Americans will develop NASH by 2025 and
as many as five million will suffer from chronic liver failure.2,5
These numbers may further stress a system in which demand for
deceased donor livers already exceeds supply.
Previous studies evaluating the outcomes of patients trans-
planted for NASH cirrhosis have shown conicting results in
terms of the effects of pre-transplant NASH on post-transplant
morbidity and mortality.2,6–8 Some suggest that recipients with
NASH have higher perioperative rates of cardiovascular events,
including myocardial infarction, acute heart failure, arrhythmia
and cerebrovascular accident.8 Additionally, pre-transplant NASH
may increase the risk for recurrent non-alcoholic fatty liver disease
(NAFLD) and allograft cirrhosis post-transplantation.9
The severely and morbidly obese [those with a body mass index
(BMI) of >35 kg/m2] are significantly more likely to undergo liver
transplantation for NASH cirrhosis than subjects of normal
weight.3,10 The effect of BMI on longterm outcomes in liver trans-
plant recipients, as distinct from the effects of NASH, is not
well understood. Historically, obesity was considered a relative
contraindication to transplantation, largely because of concerns
about technical feasibility and worse outcomes. In non-transplant
transabdominal surgery, obesity has been associated with
increases in blood loss, resource utilization, and perioperative
morbidity and mortality.11,12 In liver transplantation, severe
obesity (BMI >35 kg/m2) has also been associated with increased
rates of perioperative complications, such as wound infection and
bleeding.10,13,14 Despite initial studies evaluating its effects on
short-term outcomes and complication rates, the impacts of BMI
on longterm overall and graft survival are indeterminate. This
paper reports the present authors’ institutional experience with
liver transplantation in the obese population.
Materials and methods
A retrospective study of outcomes in all patients submitted to
primary OLT at Washington University in St Louis between 1
January 2002 and 31 December 2012 was conducted. Recipients
aged <18 years were excluded. Liver transplant recipients were
divided into six groups based on their pre-transplant BMI in
accordance with the World Health Organization classification
of obesity: Group 1 (BMI: <18.0 kg/m2); Group 2 (BMI: 18.0–
24.9 kg/m2); Group 3 (BMI: 25.0–29.9 kg/m2); Group 4 (BMI:
30.0–35.0 kg/m2); Group 5 (BMI: 35.1–40.0 kg/m2), and Group 6
(BMI: >40.0 kg/m2). Data for BMI were not adjusted for ascites
because the volume of ascites drained at the time of transplant did
not differ significantly between groups. The mean ± standard
deviation (SD) duration of follow-up was 4.5 ± 3.0 years. Pre- and
post-transplant parameters were compared among the BMI
groups (Table 1). Pre-transplant recipient variables included
patient age, race, gender, medical comorbidities [hypertension,
coronary artery disease (CAD), non-CAD cardiac disease, diabe-
tes mellitus, renal insufficiency], aetiology of liver disease, pres-
ence of hepatocellular carcinoma (HCC), haemodialysis at time
of transplant, Model for End-stage Liver Disease (MELD) score
(determined by laboratory values), and time on waiting list.
Primary outcome measures were graft and overall patient survival
at 90 days, 1 year, 3 years, 5 years and 7 years. Secondary outcome
measures included operative time, cold and warm ischaemic
times, operative transfusion requirement of ≥10 units of packed
red blood cells (uPRBC), intensive care unit (ICU) length of stay
(LoS), hospital LoS, re-exploration for bleeding, infection, disease
recurrence (hepatitis C, NASH and HCC), allograft rejection, aeti-
ology of graft failure, retransplantation, and cause of death.
Statistical analysis
Categorical variables were compared using the chi-squared test
and continuous variables were compared using Student’s t-test; a
P-value of <0.05 was considered to indicate statistical significance.
Overall patient and graft survival curves were determined using
Kaplan–Meier methods and compared using the log-rank test.
Independent predictors of patient and graft survival were deter-
mined by multivariate Cox regression analysis.
This study was approved by the Washington University School
of Medicine Institutional Review Board.
Results
Study population characteristics
A total of 785 patients met the study inclusion criteria (Table 1).
Numbers of recipients in each group were: Group 1 (BMI:
<18.0 kg/m2): n = 9 (1.2% of study population); Group 2 (BMI:
18.0–24.9 kg/m2): n = 210 (26.8%); Group 3 (BMI: 25.0–29.9 kg/
m2): n = 294 (37.5%); Group 4 (BMI: 30.0–35.0 kg/m2): n = 169
(21.5%); Group 5 (BMI: 35.1–40.0 kg/m2): n = 77 (9.8%), and
Group 6 (BMI: >40.0 kg/m2): n = 26 (3.3%). There were no sig-
nificant differences between groups with regard to age (mean ages:
47.8–55.7 years; P = NS) or race. Patients with a BMI of <18 kg/m2
or >40 kg/m2 were more likely to be female (56.6% and 63.0%,
respectively) compared with all other groups (P < 0.001). Analysis
of comorbid medical conditions demonstrated a significantly
increased rate of hypertension in patients with a BMI of
>35 kg/m2 (P = 0.001). There were no differences in prevalences of
diabetes mellitus, CAD, other (non-CAD) cardiovascular disease,
renal insufficiency or dialysis-dependent renal failure.
Liver disease and waiting time
The aetiology of liver disease varied among the groups. Chronic
hepatitis C infection was the most common cause of cirrhosis in
patients with a BMI of >18 kg/m2, whereas a BMI of <18 kg/m2
was most commonly associated with alcohol cirrhosis. Non-
alcoholic steatohepatitis represented the second leading cause
of liver disease in patients with a BMI of >35 kg/m2. Recipients
(22.8%) with a BMI of >35 kg/m2 were significantly more likely to
have NASH as the primary aetiology compared with patients in all
other groups (P < 0.0001). Only two patients (0.9%) with a BMI of
<25 kg/m2 had NASH. All groups with BMIs of >18 kg/m2 had
similar rates of HCC (26.9–38.6%; P = NS). Average MELD scores
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at the time of transplantation were 24.6 (Group 1), 19.8 (Group
2), 21.1 (Group 3), 22.2 (Group 4), 24.8 (Group 5), and 25.1
(Group 6). The difference in MELD scores between Group 2 and
Group 5 (mean MELD scores: 19.8 versus 24.8; P = 0.002) was
statistically significant. Patients with BMIs of 30.1–40.0 kg/m2
waited longer for transplant compared with patients with BMIs of
18.0–30.0 kg/m2 (280 days versus 174 days; P = 0.01). There was
no difference in need for combined liver and kidney transplanta-
tion between groups.
Perioperative outcomes and resource utilization
No significant differences between groups were detected in opera-
tive time, intraoperative transfusion requirement (≥10 uPRBC),
cold or warm ischaemic time, ICU LoS or hospital LoS (Table 2).
No significant differences between groups were detected in rates
of postoperative bleeding requiring massive transfusion or
re-exploration, hepatic artery thrombosis (HAT), portal vein
thrombosis (PVT), biliary complications or infection.
Survival
Rates of overall survival at 90 days averaged 96.5% (ranging from
94.7% in Group 5 to 100% in Groups 1 and 6; P = NS). Mean
1-year overall survival (91.0% in all patients versus 84.6% in
patients with a BMI of >40 kg/m2; P = NS) and mean 3-year
overall survival (84.6% in all patients versus 76.9% in patients
with a BMI of >40 kg/m2; P = NS) did not differ significantly
between BMI groups. Rates of overall survival at 5 years and 7
years were significantly decreased in recipients with a BMI of
>40 kg/m2 at the time of transplant (5-year survival: 51.3% versus
78.8%; 7-year survival: 38.5% versus 71.5%; P = 0.009) (Fig. 1).
No differences in graft survival were detected at 90 days, 1 year or
3 years post-transplant. Graft survival at 5 years and 7 years was
significantly decreased for patients with a BMI of >40 kg/m2 in
comparison with rates for all groups (49.0% versus 75.8%, and
36.7% versus 68.4%, respectively; P ≤ 0.02) (Fig. 2). Rates of
primary disease recurrence of hepatitis C, NASH and HCC did
not differ among groups. Secondary graft steatosis occurred in
7.1% of all allografts and trended toward a higher prevalence
in patients with a BMI of >40 kg/m2 (26.9% versus a group mean
of 7.1%; P = NS). Forty (5.1%) patients required retransplanta-
tion for graft failure. Indications for retransplantation included
primary non-function (n = 5), HAT (n = 10), PVT (n = 4),
cholangiopathy (n = 8), recurrent disease (n = 7), and chronic
rejection (n = 6). Indications for retransplantation were not
Table 1 Population demographics and pre-transplant characteristics in 785 liver transplant recipients
Variables Body mass index, kg/m2 P-value
<18.0
(n = 9)
18.0–24.9
(n = 210)
25.0–29.9
(n = 294)
30.0–35.0
(n = 169)
35.1–40.0
(n = 77)
>40.0
(n = 26)
Age, years, median 46 55 55 56 56 53 0.349
Male, % 4 (44.4) 134 (63.8) 214 (72.8) 119 (70.4) 47 (61.0) 10 (37.0) 0.001
White, % 7 (0.78) 171 (81.4) 249 (84.7) 148 (87.6) 68 (88.3) 13 (73.1) 0.267
Comorbidities, %
Diabetes 3 (33.3) 44 (21.0) 76 (25.9) 51 (30.2) 25 (32.5) 6 (23.1) 0.277
Hypertension 1 (11.1) 49 (23.3) 85 (28.9) 59 (34.9) 31 (40.3) 14 (53.8) <0.0001
Coronary artery disease 0 (0) 6 (2.9) 20 (6.8) 9 (5.3) 6 (7.8) 2 (7.7) 0.311
Other cardiac disease 0 (0) 15 (7.1) 26 (8.8) 16 (9.5) 10 (13.0) 3 (11.5) 0.621
Renal insufficiency 2 (22.2) 27 (12.9) 52 (17.7) 26 (15.4) 19 (24.7) 1 (3.8) 0.089
Renal failure on dialysis 2 (22.2) 19 (9.0) 23 (7.8) 18 (10.7) 11 (14.3) 2 (7.7) 0.497
Aetiology of liver disease, %
Hepatitis C virus 3 (33.3) 80 (38.1) 149 (50.7) 78 (46.2) 31 (40.3) 12 (46.2) 0.102
Non-alcoholic steatohepatitis 0 (0.0) 2 (0.9) 19 (6.5) 14 (8.3) 17 (22.8) 6 (23.1) <0.0001
Alcohol (primary diagnosis) 4 (44.4) 32 (15.2) 35 (11.9) 21 (12.4) 12 (15.6) 2 (7.7) 0.082
Alcohol (secondary diagnosis) 0 13 (6.2) 25 (8.5) 14 (8.3) 9 (11.7) 1 (3.8) 0.543
Primary biliary cirrhosis 0 16 (7.6) 14 (4.8) 4 (2.4) 2 (2.6) 1 (3.8) 0.15
Primary sclerosing cholangitis 1 (11.1) 18 (8.6) 11 (3.7) 4 (2.4) 1 (1.3) 0 0.012
Other 1 (11.1) 62 (29.5) 66 (22.4) 48 (28.4) 14 (18.2) 5 (19.2) 0.176
Hepatocellular carcinoma 0 (0.0) 81 (38.6) 110 (37.4) 61 (36.1) 29 (37.7) 7 (26.9) 0.836
Other
MELD score, lab-based, median 28 18 19 20 24 23 0.002
Waiting time, days, median 25 59 59 89 82 72 0.011
Liver and kidney transplant, % 1 (11.1) 11 (5.2) 13 (4.4) 6 (3.6) 4 (5.2) 0 (0) 0.719
MELD, Model for End-stage Liver Disease.
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associated with BMI. Cause of death analysis did not identify any
significant difference among BMI groups in rates of death caused
by cardiovascular, respiratory, renal or multi-organ failure, nor
deaths related to sepsis or cancer.
Multivariate Cox regression analysis of recipient characteristics
identified three independent risk factors in patient and graft
survival: a BMI >40 kg/m2; hepatitis C as end-stage liver disease
aetiology, and non-CAD cardiovascular disease (Table 3). Cox
regression analysis confirmed these factors to be independent pre-
dictors of survival: a BMI of >40 kg/m2 [hazard ratio (HR) 2.3,
95% confidence interval (CI) 1.2–4.4]; hepatitis C as aetiology of
liver disease (HR 1.4, 95% CI 1.1–1.9), and non-CAD cardiovas-
cular disease (HR 1.7, 95% CI 1.1–2.6). Similar results were
obtained in a multivariate regression analysis of graft survival.
The presence of HCC, although associated with a trend toward
diminished survival (HR 3.8), did not reach significance in the
univariate analysis (P = 0.051).
Discussion
Available data suggest that the prevalence of obesity will continue
to rise in the US population. Consequently, the number of obese
Table 2 Secondary outcomes after transplantation in 785 liver transplant recipients by patient body mass index
Body mass index, kg/m2 P-value
<18.0
(n = 9)
18.0–24.9
(n = 210)
25.0–29.9
(n = 294)
30.0–35.0
(n = 169)
35.1–40.0
(n = 77)
>40.0
(n = 26)
Operative time, h, mean 6.9 6.4 6.2 6.5 6.6 6.1 0.321
Warm ischaemia time, min, mean 38 36 37 37 36 33 0.786
Cold ischaemia time, h, mean 6.0 6.3 6.0 6.2 6.9 6.0 0.328
No intraoperative PRBC, % 0 (0.0) 53 (25.2) 65 (22.1) 51 (30.2) 15 (19.5) 4 (15.4) 0.107
≥10 units intraoperative PRBC, % 2 (22.2) 29 (13.8) 45 (15.3) 30 (17.8) 19 (24.7) 5 (19.2) 0.340
ICU LoS, days, median 6 2 2 2 3 3 0.644
Hospital LoS, days, median 12 7 7 7 9 9 0.598
Re-exploration for bleeding, % 0 (0.0) 15 (7.1) 20 (6.8) 15 (8.9) 10 (13.0) 2 (7.7) 0.468
Rejection, % 3 (33.3) 51 (24.3) 73 (24.8) 28 (16.6) 21 (27.3) 7 (26.9) 0.291
ICU, intensive care unit; LoS, length of stay; PRBC, packed red blood cells.
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Figure 1 Kaplan–Meier curves for patient survival after liver trans-
plantation in patient groups stratified by body mass index (BMI).
Group 1: <18.0 kg/m2; Group 2: 18.0–24.9 kg/m2; Group 3: 25.0–
29.9 kg/m2; Group 4: 30.0–35.0 kg/m2; Group 5: 35.1–40.0 kg/m2;
Group 6: >40 kg/m2
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Figure 2 Kaplan–Meier curves for graft survival after liver transplan-
tation in patient groups stratified by body mass index (BMI). Group
1: <18.0 kg/m2; Group 2: 18.0–24.9 kg/m2; Group 3: 25.0–29.9 kg/
m2; Group 4: 30.0–35.0 kg/m2; Group 5: 35.1–40.0 kg/m2; Group 6:
>40 kg/m2
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transplant candidates is also expected to increase, especially as
NASH becomes an increasingly significant cause of end-stage liver
disease. Short-term outcomes in obese liver transplant recipients
are often conicting and few data on longterm outcomes in
obesity have been published.
Similarly to other studies, this analysis showed that morbidly
obese patients (BMI >40 kg/m2) with liver failure are more likely
to be female, have hypertension, and have NASH as their primary
aetiology for cirrhosis. Previously published data suggested that
obesity (BMI >30 kg/m2) increases the risk for HCC in cirrhotic
livers, although this finding is not supported by the results of the
current study.15 Although it is well established that obesity corre-
lates strongly with metabolic syndrome, patients with high BMIs
in the present population did not have higher rates of diabetes or
chronic kidney disease. This may be related to selection bias in the
evaluation and approval of patients for liver transplantation. All
potential recipients undergo rigorous cardiopulmonary testing
prior to listing and thus it is possible that only the ‘healthiest’ of
the morbidly obese are activated on the waitlist. Because of the
perception that obesity alone adds risk, morbidly obese patients,
in comparison with their normal-weight counterparts, may be less
likely to be approved for transplant if they have other significant
medical conditions.
Despite similar comorbidity rates, patients with BMIs of
>35 kg/m2 waited longer for transplant and had higher MELD
scores at the time of transplantation. Other studies have docu-
mented similar findings in time on the waitlist.10,13 In this patient
cohort, it is unclear whether the longer wait times resulted in the
progression of disease and higher MELD scores or whether
severely and morbidly obese patients were evaluated and listed for
transplant later in their disease course than non-obese patients.
It is well known that a higher MELD score at the time of
transplantation increases morbidity and mortality and results in
greater resource utilization. Non-alcoholic steatohepatitis, which
is predominantly a disease of the obese, has previously been asso-
ciated with longer operative times, extended hospital LoS and
increased transfusion requirements.3 Interestingly, despite higher
rates of NASH and higher MELD scores, obese recipients in this
population did not have worse perioperative outcomes or higher
rates of complications. The small size of the sample in this previ-
ous study may have limited the statistical significance of its find-
ings. Another consideration is that patient obesity is now a
common comorbidity and thus care providers (surgeons, anaes-
thesiologists, intensivists, nurses, coordinators) are more familiar
with the challenges associated with these patients and the poten-
tial weight-related complications that may occur. Increased surgi-
cal exposure and greater experience in managing haemodynamic
changes and providing postoperative care to obese recipients
can potentially improve outcomes to the extent that a difference
between weight groups will no longer exist. Similarities in
perioperative outcomes between BMI groups may also be
reected in comparable patient and graft survival curves to 3 years
post-transplant.
Although early outcomes in patients with BMIs of >40 kg/m2
were comparable with those in patients in other BMI classes, a
BMI of >40 kg/m2 is significantly associated with reduced patient
and graft survival at 5 years and 7 years post-transplant. Potential
causes for higher rates of delayed graft loss and death include
recurrent disease (either greater incidence of recurrence or more
rapid disease progression after diagnosis of recurrence), allograft
rejection, increased incidence of secondary graft steatosis with
progression to NASH cirrhosis, increased risk for recurrent HCC,
or increased risk for death from comorbidities associated with
obesity and metabolic syndrome (specifically, cardiovascular
disease or complications of diabetes).9,16 Each of these risk factors
was studied in subgroup analyses, but none were found to signifi-
cantly differ among BMI groups. Morbidly obese transplant
recipients were more likely to develop secondary graft steatosis,
but this did not translate into increased rates of post-transplant
NASH. Recurrence of hepatitis C and HCC was not affected by
BMI. This contrasts with work by Siegel et al., who reported that
obesity nearly doubles the risk for HCC recurrence, although their
data did not achieve significance.17 In this current analysis, morbid
obesity did not predispose individuals to death from a specific
cause; the proportions of deaths from sepsis, cancer, and single-
and multi-system organ failure did not vary significantly by
weight.
Multivariate regression analysis confirmed that morbid obesity
itself is an independent risk factor for shortened graft and patient
survival. Even after controlling for the factors typically used to
Table 3 Multivariate regression analysis of risk factors for graft and
patient survival after liver transplantation
Cox regression analysis
Input variable Graft survival Patient survival
HR P-value HR P-value
Gender 0.832 0.259 0.853 0.366
Age ≥60 years 1.120 0.518 1.184 0.365
MELD score >30 1.191 0.401 1.330 0.192
Diabetes 1.235 0.199 1.317 0.112
Hypertension 0.708 0.039 0.772 0.141
Coronary artery disease 0.992 0.980 1.035 0.919
Other heart disease 1.662 0.016 1.706 0.018
Renal disease 0.902 0.667 1.065 0.797
On dialysis 1.241 0.471 1.028 0.932
Hepatitis C 1.341 0.065 1.432 0.035
Alcoholic cirrhosis 1.043 0.817 1.222 0.286
NASH 0.913 0.788 0.853 0.669
HCC 1.108 0.525 1.264 0.173
BMI >40.0 kg/m2 2.452 0.005 2.697 0.003
P-values in bold indicate statistical significance (P < 0.05).
BMI, body mass index; HCC, hepatocellular carcinoma; HR, hazard ratio;
MELD, Model for End-stage Liver Disease; NASH, non-alcoholic
steatohepatitis.
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explain the effect of BMI on mortality (e.g. NASH, cardiovascular
disease), there was a significant impact from BMI alone. Although
the present study is not unique in identifying BMI as an independ-
ent risk factor for patient and graft survival, it is the first to look
at obesity as a risk factor that is distinct from NASH in addition
to the other metabolic syndrome conditions. Whether this
trend simply reects the normal life expectancy curve for the
morbidly obese in comparison with non-obese individuals must
be established. Perhaps morbid obesity puts recipients at risk for
death from the same causes as normal-weight recipients, but at an
earlier time-point. Multiple prospective cohorts within the
general population have demonstrated a life expectancy reduction
of 10 years in individuals with BMIs of >40 kg/m2.18 Additionally,
another institution previously demonstrated that liver transplant
recipients with BMIs of >30 kg/m2 had almost double the risk
for death from all causes compared with normal-weight OLT
recipients.17
Weight reduction can reverse the longterm sequelae of obesity.
However, options for exercise-induced or surgical weight loss in
potential transplant recipients have previously been limited by
physical deconditioning and weakness, risk for bleeding as a result
of portal hypertension and coagulopathy, concerns about post-
anaesthesia hepatic decompensation, and risk for postoperative
infections. Recently, these theoretical concerns have been chal-
lenged and the performance of bariatric surgery before, during
and after liver transplantation has been reported. In one series of
20 pre-OLT patients undergoing laparoscopic sleeve gastrectomy,
only 15% suffered a serious postoperative complication and only
one patient developed hepatic insufficiency.19 A mean excess
weight loss of 61% was documented and sustained in the seven
patients who subsequently underwent liver transplantation.19
Similarly, Heimbach et al. reported minimal morbidity, sustained
weight loss and the resolution of insulin-dependent diabetes in
patients undergoing simultaneous OLT and sleeve gastrectomy.20
These early results are promising, but whether bariatric surgery
improves longterm outcomes in morbidly obese liver transplant
recipients is yet to be determined.
Aggressive management of metabolic syndrome should be a
priority in this patient population. Cardiovascular risk reduction
can be achieved with antiplatelet therapy and pharmacologic
treatment of hypertension, dyslipidaemia and glucose intoler-
ance.21,22 Consideration should be given to early steroid with-
drawal or avoidance.23 Diet modification remains an important
mechanism by which to reduce weight and obesity-associated risk
for mortality.
Although they are limited by being drawn from a single insti-
tution, the present data suggest that severe and morbid obesity
adversely affect longterm outcomes despite similar short- and
medium-term results. Further analysis is indicated to identify risk
factors for poor outcomes in morbidly obese patients and to
understand the delayed effects on patient and graft survival. With
that knowledge, interventions may be taken to improve longterm
survival in morbidly obese liver transplant recipients.
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